Research Analysts Set Expectations for ARQT FY2027 Earnings

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Equities researchers at HC Wainwright increased their FY2027 earnings per share (EPS) estimates for shares of Arcutis Biotherapeutics in a note issued to investors on Wednesday, February 26th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of $1.12 per share for the year, up from their previous estimate of $0.94. HC Wainwright currently has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is ($1.33) per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ FY2028 earnings at $1.82 EPS.

Other research analysts have also issued reports about the company. Needham & Company LLC reiterated a “buy” rating and issued a $20.00 target price on shares of Arcutis Biotherapeutics in a report on Wednesday. The Goldman Sachs Group lifted their target price on Arcutis Biotherapeutics from $13.00 to $15.00 and gave the company a “neutral” rating in a report on Thursday. Guggenheim reiterated a “buy” rating on shares of Arcutis Biotherapeutics in a report on Monday, February 24th. Finally, Mizuho lifted their target price on Arcutis Biotherapeutics from $20.00 to $21.00 and gave the company an “outperform” rating in a report on Wednesday. One analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Arcutis Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Arcutis Biotherapeutics Trading Up 7.0 %

NASDAQ:ARQT opened at $13.69 on Friday. The firm has a market cap of $1.62 billion, a PE ratio of -7.65 and a beta of 1.29. The stock has a fifty day moving average price of $13.53 and a 200 day moving average price of $11.46. Arcutis Biotherapeutics has a 12-month low of $6.99 and a 12-month high of $16.20. The company has a current ratio of 2.46, a quick ratio of 2.38 and a debt-to-equity ratio of 0.67.

Arcutis Biotherapeutics (NASDAQ:ARQT) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.19. The firm had revenue of $71.36 million for the quarter, compared to the consensus estimate of $60.52 million. Arcutis Biotherapeutics had a negative return on equity of 119.11% and a negative net margin of 140.97%.

Hedge Funds Weigh In On Arcutis Biotherapeutics

Several hedge funds have recently made changes to their positions in ARQT. Point72 DIFC Ltd purchased a new position in shares of Arcutis Biotherapeutics during the third quarter worth about $25,000. GF Fund Management CO. LTD. purchased a new position in shares of Arcutis Biotherapeutics during the fourth quarter worth about $34,000. Venturi Wealth Management LLC purchased a new position in shares of Arcutis Biotherapeutics during the fourth quarter worth about $46,000. Erste Asset Management GmbH purchased a new position in shares of Arcutis Biotherapeutics during the third quarter worth about $104,000. Finally, Victory Capital Management Inc. grew its holdings in shares of Arcutis Biotherapeutics by 9.9% during the third quarter. Victory Capital Management Inc. now owns 12,843 shares of the company’s stock worth $119,000 after purchasing an additional 1,155 shares during the last quarter.

Insider Buying and Selling at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Todd Franklin Watanabe sold 15,000 shares of the firm’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $15.17, for a total value of $227,550.00. Following the sale, the insider now directly owns 823,430 shares in the company, valued at $12,491,433.10. This trade represents a 1.79 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Masaru Matsuda sold 8,338 shares of the firm’s stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $12.70, for a total value of $105,892.60. Following the completion of the sale, the insider now owns 178,692 shares in the company, valued at approximately $2,269,388.40. This represents a 4.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 55,029 shares of company stock worth $756,017 over the last ninety days. Corporate insiders own 9.50% of the company’s stock.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.